PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAbacavir
Ziagen(abacavir)
Abacavir, Abacavir / Lamivudine, Abacavir / Lamivudine /, Kivexa, Triumeq, Ziagen (abacavir) is a small molecule pharmaceutical. Abacavir was first approved as Ziagen on 1998-12-17. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Abacavir, Ziagen (discontinued: Abacavir, Ziagen)
Combinations
Abacavir lamivudine, Abacavir sulfate, lamivudine zidovudine, Triumeq (discontinued: Abacavir lamivudine, Epzicom, Trizivir)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abacavir sulfate
Tradename
Company
Number
Date
Products
ZIAGENViiV HealthcareN-020978 RX1998-12-17
1 products, RLD, RS
Show 1 discontinued
Abacavir sulfate
+
Dolutegravir sodium
+
Lamivudine
Tradename
Company
Number
Date
Products
TRIUMEQ PDViiV HealthcareN-215413 RX2022-03-30
1 products, RLD, RS
TRIUMEQViiV HealthcareN-205551 RX2014-08-22
1 products, RLD, RS
Abacavir sulfate
+
Lamivudine
Tradename
Company
Number
Date
Products
ABACAVIR SULFATE AND LAMIVUDINEMylanN-204311 DISCN2023-12-22
1 products, RLD
EPZICOMViiV HealthcareN-021652 DISCN2004-08-02
1 products, RLD
Hide discontinued
Abacavir sulfate
+
Lamivudine
+
Zidovudine
Tradename
Company
Number
Date
Products
TRIZIVIRViiV HealthcareN-021205 DISCN2000-11-14
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
abacavirANDA2024-08-01
abacavir and lamivudineANDA2024-12-11
abacavir sulfateANDA2022-06-14
abacavir sulfate, lamivudine and zidovudineANDA2013-12-17
abacavir, lamivudine and zidovudineANDA2023-10-31
epzicomNew Drug Application2022-12-14
triumeqNew Drug Application2021-03-23
triumeq triumeq pdNew Drug Application2024-07-08
trizivirNew Drug Application2014-04-24
ziagenNew Drug Application2023-09-29
Agency Specific
FDA
EMA
Expiration
Code
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE
2026-12-15PED
2026-06-15M-294
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE
2026-12-15PED
2026-06-15NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare
92429862029-12-08DS, DP
81293852027-10-05DS, DP
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF06: Abacavir
J05AR: Antivirals for treatment of hiv infections, combinations
J05AR02: Lamivudine and abacavir
J05AR04: Zidovudine, lamivudine and abacavir
J05AR13: Lamivudine, abacavir and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
254 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B202339654236200
InfectionsD007239EFO_00005448142071665
Acquired immunodeficiency syndromeD000163EFO_0000765B208102391261
HivD006678O98.745718335
Communicable diseasesD00314113114423
Immunologic deficiency syndromesD007153D84.91453214
LipodystrophyD008060E88.128111
Cardiovascular diseasesD002318EFO_0000319I981438
Hiv-1D0154971135
Hiv-associated lipodystrophy syndromeD039682EFO_100134844
Show 20 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HepatitisD006505K75.91124
Hepatitis aD006506EFO_0007305B151124
Hepatitis cD006526B19.21113
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21123
Motor neuron diseaseD016472EFO_0003782G12.2123
SclerosisD012598123
Chronic hepatitis cD019698EFO_0004220B18.2112
MalariaD008288EFO_0001068B5411
SarcomaD012509111
Kaposi sarcomaD012514C46111
Show 5 more
Indications Phases 2
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients33
Hiv seronegativityD01802311
Crush injuriesD000071576T14.811
PsoriasisD011565EFO_0000676L4011
GliomaD005910EFO_000052011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hepatitis bD00650922
Chronic hepatitis bD019694EFO_0004239B18.111
Wasting syndromeD01928211
CachexiaD002100R6411
Drug hypersensitivityD004342EFO_0009482T88.711
Liver transplantationD016031EFO_001068211
HypotensionD007022EFO_0005251I9511
Platelet aggregationD010974GO_007052711
Kidney calculiD007669EFO_0004253N2011
Bone fracturesD050723EFO_0003931T14.811
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAbacavir
INNabacavir
Description
Abacavir is a 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug allergen.
Classification
Small molecule
Drug classantivirals: carbocyclic nucleosides
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1
Identifiers
PDB
CAS-ID136470-78-5
RxCUI
ChEMBL IDCHEMBL1380
ChEBI ID421707
PubChem CID441300
DrugBankDB01048
UNII IDWR2TIP26VS (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Abacavir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Abacavir
+
Lamivudine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Abacavir
+
Lamivudine
+
Zidovudine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 11,253 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abacavir, Abacavir and lamivudine, Abacavir sulfate, Abacavir sulfate, lamivudine and zidovudine, Abacavir, lamivudine and zidovudine, Epzicom, Triumeq, Triumeq triumeq pd, Trizivir, Ziagen
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
21,545 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use